BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32385899)

  • 21. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
    BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
    Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H
    Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
    Das B; Jain N; Mallick B
    Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
    Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
    Jin Y; Wang L; Lou H; Song C; He X; Ding M
    Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
    Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
    Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
    [No Abstract]   [Full Text] [Related]  

  • 29. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
    Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
    Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.
    Su YF; Wu TF; Ko JL; Tsai HT; Tee YT; Chien MH; Chou CH; Lin WL; Low HY; Chou MY; Yang SF; Wang PH
    PLoS One; 2014; 9(3):e91644. PubMed ID: 24637958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
    Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
    Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
    Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
    BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential mechanism of RRM2 for promoting Cervical Cancer based on weighted gene co-expression network analysis.
    Wang J; Yi Y; Chen Y; Xiong Y; Zhang W
    Int J Med Sci; 2020; 17(15):2362-2372. PubMed ID: 32922202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
    Kolesar J; Huang W; Eickhoff J; Hahn K; Alberti D; Attia S; Schelman W; Holen K; Traynor A; Ivy P; Wilding G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):79-86. PubMed ID: 18941749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
    Fang Z; Lin A; Chen J; Zhang X; Liu H; Li H; Hu Y; Zhang X; Zhang J; Qiu L; Mei L; Shao J; Chen X
    Oncotarget; 2016 Nov; 7(47):78055-78068. PubMed ID: 27801665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
    Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
    Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
    Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
    Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
    Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.